Ethris

Our CEO, Carsten Rudolph, Dr. recently discussed how Ethris is pioneering mRNA therpies for Lung diseases by leveraging our SNIM RNA and SNAP delivery platform with Vera Kovacevic on the Life Science Podcast. Please find the episode here: https://lnkd.in/d8j8Rk36

Our Chief Medical Officer Thomas Langenickel will present our recent advancements to treat Primary Ciliary Dyskinesia today, September 6th, at the PCD Annual Research Meeting in Vienna. Find more information here: https://lnkd.in/dWE-idmP

Our Chief Medical Officer Thomas Langenickel discussed the potential of mRNA therapeutics in respiratory medicine Vera Kovacevic from Xtalks. He highlighted the positive interim results from the ongoing Phase I trial of our lead program ETH47 for the treatment of asthma and how Ethris managed to overcome the challenges of developing a mRNA drug product. Find the full interview here: https://lnkd.in/deRPKDyz

We are thrilled to announce positive inital data demonstrating nasal delivery of our mRNA lead candidate ETH47 for the treatment of uncontrolled asthma.   ETH47 resulted in a dose-dependent increase in target protein expression in the nasal cavity and was generally safe and well-tolerated and a full data readout is expected in Q3 this year. Learn more: https://lnkd.in/dNkG7XCP

We are thrilled to announce that Ethris received a total of €8 million in new funding: $5 million from Bill & Melinda Gates Foundation to prepare our lead candidate ETH47 for a phase 2 study and an additional €3 million investment by Cipla which had earlier invested €15 million in 2022. Learn more: https://lnkd.in/dSxiUwvc

We are happy to present at this year's International Cell&Gene Therapy China Summit. Our CEO, Carsten Rudolph, Dr., will speak about Ethris' mRNA and LNP platform on May 24th at 2:50pm.

Our CMO, Thomas Langenickel, will speak at this year's PCD Medical Board organized by the PCD Support UK in London, on May 17. His session will focus on Ethris' inhaled mRNA therapy for the treatment of people with PCD.

Our Chief Technology Officer, Christian Plank, will be speaking at TIDES USA in Boston, USA, on May 16 at 3:00pm. His session will focus on our recent advancements of RNA therapeutics for Primary Ciliary Dyskinesia.

We are excited to attend this year's BioEquity in San Sebastian from May 12-14th. Please join our CEO Carsten Rudolph, Dr. presenting Ethris' recent advancements in respiratory RNA medicine on May 13th at 10:15 am.

We are excited to attend the LSX World Congress in London this week to present the progress of our programs and technology platform to potential partners and investors. Feel free to reach out and schedule a meeting with us!